Eric J. Small, MD

Clinical Professor, Departments of Medicine and Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF
Deputy Director and Associate Director, Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center
Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF

Phone: (415) 353-7171 (appts)
Box 1711, UCSF
San Francisco, CA 94143-1711

View on UCSF Profiles

Additional Websites

• Physician Referral Directory

Education

Stanford University, Stanford, CA, BS, 1980, Biology
Case Western Reserve University of Medicine, Cleveland, Ohio, MD, 1985, Medicine
Beth Israel Hospital, Boston, MA, Internship and Residency, 1988, Internal Medicine
University of California San Francisco, CA, Fellowship, 1991, Hematology/Oncology

Professional Experience

• 1982-1983
  Pathology Fellowship, Department of Pathology, Case Western Reserve Univ., Cleveland, OH
• 1985-1988
  Internal Medicine Internship and Residency Training Program, Beth Israel Hospital, Boston, MA
• 1988-1989
  Clinical Fellow, Cancer Research Institute, UCSF, San Francisco, CA
• 1989-1991
  Research Fellow, Cancer Research Institute, (Dr. Marc Shuman) UCSF, San Francisco, CA
• 1991-1997
  Assistant Clinical Professor of Medicine, UCSF, San Francisco, CA
• 1991-present
  Head, Urologic Medical Oncology, Division of Hematology/Oncology, UCSF, San Francisco, CA
• 1996-present
  Co-Director, Urologic Oncology Program, UCSF, San Francisco, CA
• 1997-2001
  Associate Clinical Professor of Medicine and Urology, UCSF, San Francisco, CA
• 1999-present
  Chair, Genitourinary Committee, Cancer and Leukemia Group B (CALGB)
• 2001-present
  Professor in Residence of Medicine and Urology, UCSF, San Francisco, CA
• 2007-2009
  Interim Chief, Division of Hematology and Oncology, UCSF, San Francisco, CA
• 2007-present
  Director, Investigational Trials Resource, UCSF Helen Diller Family Comprehensive Cancer Center
• 2009-present
  Chief, Division of Hematology/Oncology, UCSF, San Francisco, CA
• 2009-present
  Deputy Director and Director of Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

• 1978
  Biomedical Research Grant, The Jackson Laboratory, Bar Harbour, ME
• 1980
  NIH Research Support Grant, Case Western Reserve University, Cleveland, OH
• 1984
  Alpha Omega Alpha Honor Medical Society
• 1997
  Prostate Cancer Foundation Therapy Consortium
• 2006-present
  Stanford W. and Norman R. Ascherman Endowed Chair

Selected Publications

1. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 1; 11(4):446-75.
   View on PubMed
2. Cha E, Small EJ. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med. 2013 Apr; 2(2):243-52.
   View on PubMed
3. Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with Cisplatin-based chemotherapy. J Natl Cancer Inst. 2013 Apr 3; 105(7):499-503.
   View on PubMed
4. Goodwin PJ, Ballman KV, Small EJ, Cannistra SA. Evaluation of treatment benefit in journal of clinical oncology. J Clin Oncol. 2013 Mar 20; 31(9):1123-4.
   View on PubMed
5. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48.
   View on PubMed
6. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol. 2013 Feb 1; 31(4):412-9.
   View on PubMed
7. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012 Oct 1; 189(7):3759-66.
   View on PubMed
8. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012 Oct; 188(4):1164-9.
   View on PubMed
9. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1107-9; author reply 1109-12.
   View on PubMed
10. Bluestone JA, Small EJ. The future of cancer treatment: will it include immunotherapy? Cancer Cell. 2012 Jul 10; 22(1):7-8.
    View on PubMed
11. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 1; 30(13):1534-40.
    View on PubMed
12. Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 2012 Sep 1; 118(17):4139-47.
    View on PubMed
13. Small EJ, de Bono JS. Prostate cancer: evolution or revolution? J Clin Oncol. 2011 Sep 20; 29(27):3595-8.
    View on PubMed
14. Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer. 2011 Dec 15; 117(24):5579-88.
    View on PubMed
15. Small EJ, Penson DF, Sartor O. The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Jul; 9(7 Suppl 13):1-16.
    View on PubMed
16. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61.
    View on PubMed
17. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200.
    View on PubMed
18. Stadler WM, Phillips G, George DJ, Halabi S, Small E. Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol. 2010 Nov 20; 28(33):e692-3; author reply e694.
    View on PubMed
19. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14.
    View on PubMed
20. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011 Feb 1; 117(3):526-33.
    View on PubMed

View on UCSF Profiles